SLXN

Silexion Therapeutics Ltd. SLXN

Net profit

EBITDA

P/E Ratio

Capitalization

Performance

Periode SLXN ENVB INDP SLRX CARM ONCO SPRC JSPR GTBP ATXI
6M -68.35 % -27.41 % -72.52 % -57.41 % -76.80 % -33.94 % -29.09 % -38.53 % -69.05 % 169.66 %
YTD -87.44 % -84.61 % -83.79 % -82.38 % -89.62 % -93.42 % -47.94 % -87.67 % -75.05 % -63.21 %
1Y -90.84 % -85.83 % -89.09 % -79.82 % -95.19 % -99.25 % -8.33 % -85.78 % -63.14 % -66.02 %
3Y -98.58 % -98.35 % -92.67 % -99.23 % -99.55 % -99.92 % -99.19 % -66.23 % -98.53 % -99.72 %
5Y -98.58 % -99.98 % -99.28 % -99.82 % -99.80 % -100.00 % -99.83 % -97.38 % -99.39 % -99.98 %
10Y -98.58 % -100.00 % -99.97 % -100.00 % -99.92 % -100.00 % -99.83 % -97.35 % -100.00 % -99.99 %
From the beginning -98.58 % -100.00 % -99.97 % -100.00 % -99.98 % -100.00 % -99.83 % -97.35 % -100.00 % -99.99 %

Dividend

Enveric Biosciences, Inc.

Carisma Therapeutics, Inc.